Phase 2 N=53 Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients
Breast Cancer
Primary: Diarrhea for >= 2 Consecutive Days — 68; 69.6; 65.2; 72.2 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=139 Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
Chemotherapy-induced Diarrhea
Primary: Percentage of Participants Developing Diarrhea (Grade 1 to 4) — 76.1; 78.9 Percentage of Participants
Phase 2 N=100 Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
Chemotherapeutic Agent Toxicity · Colorectal Cancer · Diarrhea
Primary: Number of Participants With Grade 3/4 Diarrhea — 27; 26; 7; 3 Participants
Phase 2 N=498 Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)
Drug and/or Toxin-induced Diarrhea
Primary: Proportion of Patients Experiencing a Maximum Grade ≥ 2 Diarrhea During the First Cycle of Chemotherapy in the Target Population — 2.5; 5.0; 5.8; 9.8 percentage of…
Phase 2 N=11 Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
HER2-positive Breast Cancer · Breast Adenocarcinoma · Stage II Breast Cancer AJCC v6 and v7
Primary: Percentage of Participants With Grade 3 or Greater Diarrhea — 29; 50 percentage of participants
Phase 4 N=20 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Ovarian Cancer · Uterine Cancer
Primary: Overall Complete Response Rate — 10; 10 percentage of participants
N/A N=300 Management of Nausea and Vomiting Chemotherapy-induced in Normandy
Cancer · Nausea · Vomiting
Primary: Number of Participants With Acute Nausea and Vomiting — 101 Participants
Phase 2 N=33 A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Proportion of Participants With Grade 2-4 Toxicities — 0.63; 0.40 proportion of participants
Phase 3 N=87 Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy
Diarrhea · Gastrointestinal Complications · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Severity of Diarrhea Toxicity as Measured by the CTCAE v4.0 During and After Radiotherapy (RT) — 10; 10; 13; 15 Participants — p=0.41
Phase 2 N=95 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
Metastatic Colorectal Cancer · Skin Rash · Skin Toxicities
Primary: Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period — 29; 62 percentage of participants
Phase 2 N=85 Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
Chemotherapy-induced Nausea and Vomiting
Primary: Complete Response Rate for Delayed Chemotherapy Induced Nausea & Vomiting — 13 participants
Phase 2 N=54 Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
Colorectal Cancer · Nausea and Vomiting
Primary: Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy. — 54 Participants
Phase 2 N=41 Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Acute Myeloid Leukemia
Primary: Percentage of Participants With Incidence of Vomiting/Retching From Day 1 Through End of Day 5 — 26.3 percentage of particpants
Phase 2 N=563 An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Early Stage HER2+ Breast Cancer
Primary: Percentage of Patients With Grade 3 or Higher Diarrhea, According to NCI CTCAE v4.0. — 30.7; 28.1; 20.6; 32.7 Percentage of participants
Phase 3 N=225 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
Rectal Mucinous Adenocarcinoma · Rectal Signet Ring Cell Adenocarcinoma · Recurrent Rectal Carcinoma
Primary: 3-year Overall Survival Rate — 0.965; 0.843; 0.870 proportion of patients — p=0.35
Phase 2 N=85 Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
Chemotherapy-Induced Nausea and Vomiting · Ovarian Cancer
Primary: Efficacy of the Aprepitant/Ramosetron/Dexamethasone Regimen in Terms of the Proportion of Patients With a Complete Response (CR) During the 120 Hour Following Initiation…
Phase 4 N=212 Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
Breast Cancer
Primary: Number of Participants With Complete Response (CR) — 161 Participants
Phase 2 N=79 Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
Colorectal Cancer
Primary: The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for…
N/A N=64 Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
Colorectal Cancer · Nausea · Vomiting
Primary: Percentages of Participants by Gender Who Reported Nausea During the First Week of Chemotherapy — 64; 34; 100 percentage of participants — p=.05
Phase 3 N=380 Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Hematopoietic/Lymphoid Cancer · Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients With no Nausea — 73.8; 45.3; 42.4; 25.4 percentage of participants
Phase 3 N=40 ADAM-Afatinib Diarrhea Assessment and Management
Carcinoma, Non-Small-Cell Lung
Primary: Occurence of CTCAE Grade >= 2 Diarrhea — 72.20; 31.80 Percentage of participants
Phase 3 N=231 Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Neurotoxicity · Pain · Peripheral Neuropathy
Primary: Change in Average Pain From Week 1 to Week 5, as Measured by the BPI-SF Average Pain Severity Item — 1.06; 0.34 units on a scale — p=0.003
N/A N=30 Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy
Gastrointestinal Cancer · Nausea Post Chemotherapy
Primary: Percentage of Participants With Control of Vomiting and Rescue Medication Control — 26.9 percentage of participants
Phase 2 N=50 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
Cancer Other Than Leukemia
Primary: Dose of Arsenic That Blocks Activation of p53 — 0.005 mg/kg
Phase 3 N=69 Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Germ Cell Tumors
Primary: Complete Response. — 47; 15 percentage of evaluable subjects
Phase 2 N=9 Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Clostridium Difficile Infection · Hematologic Diseases · Bone Marrow Transplant
Primary: Changes in Clostridium Difficile Bacterial Loads in the Stool — 62102500.00; 40000000.00; 7752750.00; 185000.00 CFUs
N/A N=44 Programs To Support You During Chemotherapy
Depression · Fatigue · Stage IIA Colorectal Cancer
Primary: Fatigue Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) — 53.1; 56.8; 53.0; 57.2 score on a scale
Phase 2 N=321 Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer
Rectal Cancer
Primary: Number of Participants With Disease Recurrence — 53; 39 Participants — p=0.047
N/A N=61 Chemotherapy Induced Peripheral Neuropathy. Could Physical Therapy Help Treat Symptoms?
Breast Cancer · Peripheral Neuropathy, Secondary to Drugs or Chemicals
Primary: Percentage of Participants With 'Pain' or 'no Pain' as Measured by the Numeric Pain Rating Scale — 30; 49; 70; 51 percentage of participants — p=0.053
Phase 3 N=165 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Chemotherapy-induced Thrombocytopenia
Primary: Percentage of Participants Who Had Thrombocytopenia-induced Dose Modification — 84.4; 35.7 percentage of participants — p=< 0.001